# MK2 Inhibitor in Combination With mFOLFIRINOX for Untreated Metastatic Pancreatic Ductal Adenocarcinoma

> **NCT06648434** · PHASE1 · RECRUITING · sponsor: **Washington University School of Medicine** · enrollment: 51 (estimated)

## Conditions studied

- Metastatic Pancreatic Ductal Adenocarcinoma
- Pancreatic Cancer
- Cancer of the Pancreas

## Interventions

- **DRUG:** Zunsemetinib
- **DRUG:** mFOLFIRINOX

## Key facts

- **NCT ID:** NCT06648434
- **Lead sponsor:** Washington University School of Medicine
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-06-13
- **Primary completion:** 2027-06-30
- **Final completion:** 2030-05-31
- **Target enrollment:** 51 (ESTIMATED)
- **Last updated:** 2026-04-30

## Collaborators

- National Cancer Institute (NCI)
- Aclaris Therapeutics, Inc.

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06648434

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06648434, "MK2 Inhibitor in Combination With mFOLFIRINOX for Untreated Metastatic Pancreatic Ductal Adenocarcinoma". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT06648434. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*